Sucampo Pharmaceuticals Inc

Sucampo Pharmaceuticals — Q1 2017 Earnings Presentation

24 slides from Sucampo Pharmaceuticals's earnings presentation, May 3, 2017

  1. Slide 1: First Quarter 2017 Corporate Update and Financial Results

    First Quarter 2017 Corporate Update and Financial Results May 3, 2017 1

  2. Slide 2: Introductions and Forward-Looking Statements

    Introductions and Forward - Looking Statements Silvia Taylor, SVP Investor Relations & Corporate Affairs

  3. Slide 3: Agenda

    Agenda Introductions and Forward - Looking Statements Silvia Taylor Corporate Update Peter Greenleaf Pipeline Update Peter Kiener , D. Phil Financial Update Peter Pfreundschuh Closing Remarks Peter Greenleaf 3

  4. Slide 4: Forward Looking Statement

    Forward Looking Statement This presentation contains "forward - looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to dif fer

  5. Slide 5: Non-GAAP Metrics

    Non - GAAP Metrics This presentation contains three financial metrics ( Adjusted Net Income, EBITDA , Adjusted EBITDA and Free Cash Flow ) that are considered “non - GAAP” financial metrics under applicable Securities and Exchange Commission rules and regulations. These non - GAAP financial metrics

  6. Slide 6: Q1 2017 Corporate Update

    Q1 2017 Corporate Update Peter Greenleaf, Chairman and CEO

  7. Slide 7: Vtesse Inc. Acquisition

    Vtesse Inc. Acquisition • Sucampo acquired Vtesse, including its orphan drug candidate for Niemann - Pick Type C1 (NPC - 1), VTS - 270, for $200 million upfront consideration • VTS - 270 for the treatment of NPC - 1 in global pivotal registration program • Ultra - rare disorder with devastating and

  8. Slide 8: Strong Q1 2017 U.S. AMITIZA Performance

    Strong Q1 2017 U.S. AMITIZA Performance • Takeda’s AMITIZA net sales for royalty calculation purposes • Q1 grew 12% YoY to $102M • Driven by increased volume and price • Royalty revenue grew 12% YoY to $18M • U.S. AMITIZA product sales to Takeda of $11M • Total U.S. revenue of $30M • AMITIZA TRx • Q

  9. Slide 9: Strong Japan AMITIZA Performance

    Strong Japan AMITIZA Performance • Sucampo Q1 revenue: $20M, growth of 38% YoY • Growth driven by volume • Increased 34% YoY • Patient demand remains strong 9

  10. Slide 10: 2017 Guidance Maintained

    2017 Guidance Maintained • Total revenue: $220 million to $230 million • Adjusted net income: $56 million to $66 million • Adjusted EBITDA: $109 million to $119 million • Adjusted EPS: $1.00 to $1.10 • Free cash flow of $86 million to $96 million 10

  11. Slide 11: Pipeline Update

    Pipeline Update Peter Kiener, D. Phil, CSO 11

  12. Slide 12: VTS-270 for Treatment of NPC-1

    VTS - 270 for Treatment of NPC - 1 • VTS - 270 is a highly - purified mixture of 2 - hydroxypropyl - ß - cyclodextrins with a specific compositional fingerprint that targets cholesterol and sphingolipid storage • Early pre - clinical and clinical data have shown encouraging results • Recently, data

  13. Slide 13: VTS-270 Pivotal Trial

    VTS - 270 Pivotal Trial 13 13 Until regulatory decision • IT injections every 2 weeks • Trial fully enrolled • Pivotal data expected in mid - 2018 • Potential regulatory approval in U.S. and EU in 1H19 • Phase 1 patients currently in Part C on therapy >36 months 12 months for any single subject Part

  14. Slide 14: Product Pipeline

    Product Pipeline 14 Sucampo Program Option

  15. Slide 15: Financial Update

    Financial Update Peter Pfreundschuh , CFO 15

  16. Slide 16: Continued Financial and Operational Performance

    Continued Financial and Operational Performance Q1 REVENUE • Overall revenue grew 19% YoY to $56M • Product sales grew 28% to $34M • Product royalty revenue grew 12% to $18M EARNINGS Summary of Results Q1 - 17 % Increase / (Decrease) over Q1 - 16 Net Income GAAP $4.6M 214% EPS GAAP – diluted $0.10 2

  17. Slide 17: Q1 Revenue

    Q1 Revenue 17 [VALUE] 1.4 1.9 0.2 56.3 47.2 0.0 10.0 20.0 30.0 40.0 50.0 60.0 Q1 2016 Amitiza Japan product sales Amitiza US product sales Amitiza US royalty Other Q1 2017

  18. Slide 18: Q1 Adjusted Net Income

    Q1 Adjusted Net Income 18 13.0 8.9 7.1 3.0 0.3 11.5 6.5 3.9 0.7 9.8 0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 Q1 2016 Gross margin Acquisition related exp Non-Operating expense Restructuring/ severance Inventory step-up Tax rate R&D License Option Exp Other Q1 2017

  19. Slide 19: Key Balance Sheet Items

    Key Balance Sheet Items Balance Sheet End 3/31/17 End 12/31/16 Cash, Cash Equivalents and Restricted Cash $243.7M $45.2M $198.5M Notes Payable $291.0M $0.5M $290.5M Net Debt $47.3M. ($44.7M) $92.0M $ sucampo

  20. Slide 20: Closing Remarks

    Closing Remarks Peter Greenleaf, Chairman and CEO 20

  21. Slide 21: 2017 Areas of Focus

    2017 Areas of Focus 1. Deliver outstanding financial performance 2. Progress proprietary pipeline programs 3. Evaluate and execute on additional opportunities for growth

  22. Slide 22: Q&A Session

    Q&A Session

  23. Slide 23: Reconciliation of GAAP Net Income to Non-GAAP Net Income

    Reconciliation of GAAP Net Loss to Non - GAAP Net Income RECONCILIATION OF GAAP NET INCOME TO ADJUSTED NET INCOME (in thousands, except per share amounts) Three Months Ended Three Months Ended March 31, 2017 March 31, 2016 Adjusted Net Income: GAAP net income (loss) 4,624 (4,057) Amortization intang

  24. Slide 24: Reconciliation of Income from Operations to Adjusted EBITDA

    Reconciliation of Income from Operations to Adjusted EBITDA RECONCILIATION OF GAAP NET INCOME TO ADJUSTED EBITDA (in thousands, except per share amounts) Three Months Ended Three Months Ended March 31, 2017 March 31, 2016 GAAP net income 4,624 (4,057) Adjustments: Taxes 3,585 (3,038) Interest expens

Sucampo Pharmaceuticals — Q1 2017 Earnings Presentation on 6ix